- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- GLENMARK PHARMA - ABBOTT INDIA
GLENMARK PHARMA vs ABBOTT INDIA - Comparison Results
GLENMARK PHARMA 
Change
Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More
ABBOTT INDIA
Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More
Current Valuations
| GLENMARK PHARMA | ABBOTT INDIA | GLENMARK PHARMA/ ABBOTT INDIA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 23.1 | 35.7 | 64.8% | View Chart |
| P/BV | x | 3.2 | 9.2 | 34.3% | View Chart |
| Dividend Yield | % | 0.3 | 0.8 | 44.3% |
Financials
 GLENMARK PHARMA  ABBOTT INDIA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| GLENMARK PHARMA Mar-18 |
ABBOTT INDIA Mar-18 |
GLENMARK PHARMA/ ABBOTT INDIA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 930 | 6,110 | 15.2% | |
| Low | Rs | 517 | 3,996 | 12.9% | |
| Sales per share (Unadj.) | Rs | 322.6 | 1,552.2 | 20.8% | |
| Earnings per share (Unadj.) | Rs | 28.5 | 188.8 | 15.1% | |
| Cash flow per share (Unadj.) | Rs | 39.2 | 196.4 | 20.0% | |
| Dividends per share (Unadj.) | Rs | 2.00 | 55.00 | 3.6% | |
| Dividend yield (eoy) | % | 0.3 | 1.1 | 25.4% | |
| Book value per share (Unadj.) | Rs | 183.0 | 796.6 | 23.0% | |
| Shares outstanding (eoy) | m | 282.17 | 21.25 | 1,327.9% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 2.2 | 3.3 | 68.9% | |
| Avg P/E ratio | x | 25.4 | 26.8 | 94.9% | |
| P/CF ratio (eoy) | x | 18.5 | 25.7 | 71.8% | |
| Price / Book Value ratio | x | 4.0 | 6.3 | 62.3% | |
| Dividend payout | % | 7.0 | 29.1 | 24.1% | |
| Avg Mkt Cap | Rs m | 204,206 | 107,376 | 190.2% | |
| No. of employees | `000 | 13.7 | 3.3 | 412.9% | |
| Total wages/salary | Rs m | 18,718 | 3,937 | 475.5% | |
| Avg. sales/employee | Rs Th | 6,636.8 | 9,929.3 | 66.8% | |
| Avg. wages/employee | Rs Th | 1,364.7 | 1,185.1 | 115.2% | |
| Avg. net profit/employee | Rs Th | 586.1 | 1,207.7 | 48.5% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 91,031 | 32,985 | 276.0% | |
| Other income | Rs m | 914 | 1,170 | 78.1% | |
| Total revenues | Rs m | 91,945 | 34,155 | 269.2% | |
| Gross profit | Rs m | 16,154 | 5,245 | 308.0% | |
| Depreciation | Rs m | 3,019 | 162 | 1,864.6% | |
| Interest | Rs m | 2,856 | 38 | 7,475.7% | |
| Profit before tax | Rs m | 11,193 | 6,215 | 180.1% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 3,155 | 2,203 | 143.2% | |
| Profit after tax | Rs m | 8,039 | 4,012 | 200.4% | |
| Gross profit margin | % | 17.7 | 15.9 | 111.6% | |
| Effective tax rate | % | 28.2 | 35.4 | 79.5% | |
| Net profit margin | % | 8.8 | 12.2 | 72.6% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 69,887 | 22,655 | 308.5% | |
| Current liabilities | Rs m | 32,879 | 6,681 | 492.1% | |
| Net working cap to sales | % | 40.7 | 48.4 | 83.9% | |
| Current ratio | x | 2.1 | 3.4 | 62.7% | |
| Inventory Days | Days | 81 | 65 | 125.7% | |
| Debtors Days | Days | 93 | 29 | 320.7% | |
| Net fixed assets | Rs m | 28,892 | 835 | 3,458.1% | |
| Share capital | Rs m | 282 | 213 | 132.8% | |
| "Free" reserves | Rs m | 51,353 | 16,715 | 307.2% | |
| Net worth | Rs m | 51,635 | 16,928 | 305.0% | |
| Long term debt | Rs m | 41,418 | 0 | - | |
| Total assets | Rs m | 125,954 | 24,162 | 521.3% | |
| Interest coverage | x | 4.9 | 163.7 | 3.0% | |
| Debt to equity ratio | x | 0.8 | 0 | - | |
| Sales to assets ratio | x | 0.7 | 1.4 | 52.9% | |
| Return on assets | % | 8.6 | 16.8 | 51.6% | |
| Return on equity | % | 15.6 | 23.7 | 65.7% | |
| Return on capital | % | 15.1 | 36.9 | 40.9% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 36,317 | 369 | 9,854.3% | |
| Fx outflow | Rs m | 9,720 | 3,807 | 255.3% | |
| Net fx | Rs m | 26,598 | -3,438 | -773.6% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 16,481 | 1,527 | 1,079.3% | |
| From Investments | Rs m | -10,133 | -2,148 | 471.7% | |
| From Financial Activity | Rs m | -4,685 | -1,024 | 457.4% | |
| Net Cashflow | Rs m | 1,770 | -1,646 | -107.6% | |
Share Holding
| Indian Promoters | % | 48.3 | 0.0 | - | |
| Foreign collaborators | % | 0.0 | 75.0 | - | |
| Indian inst/Mut Fund | % | 6.9 | 7.9 | 87.3% | |
| FIIs | % | 34.4 | 0.1 | 34,400.0% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 10.5 | 17.1 | 61.4% | |
| Shareholders | 56,727 | 18,270 | 310.5% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare GLENMARK PHARMA With: FULFORD INDIA VENUS REMEDIES STERLING BIOTECH CADILA HEALTHCARE AUROBINDO PHARMA
Compare GLENMARK PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends 383 Points Lower; Realty and Auto Stocks Drag(Closing)
After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.
Related Views on News
GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Sep 27, 2018 | Updated on Sep 27, 2018Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.
ABBOTT INDIA Announces Quarterly Results (1QFY19); Net Profit Up 70.8% (Quarterly Result Update)
Aug 20, 2018 | Updated on Aug 20, 2018For the quarter ended June 2018, ABBOTT INDIA has posted a net profit of Rs 824 m (up 70.8% YoY). Sales on the other hand came in at Rs 8 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
More Views on NewsMost Popular
Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)
Oct 5, 2018Find companies with long term durable moats, which are correcting with the current broader market sell-off.
Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)
Oct 5, 2018Ajit Dayal on the crisis in the market and in the mutual fund industry.
This Market Crash could be the Biggest Wealth Creating Opportunity Since 2008(Profit Hunter)
Oct 8, 2018While widespread fear is the friend of a value investor, serving up bargain purchases; personal fear is an investor's biggest enemy.
IPO Market Feels the Heat of the Market Crash(Sector Info)
Oct 12, 2018The sentiments in primary market have also deteriorated amid the stock market correction. Most listed IPOs of 2018 are trading below their issue price.
Are These Deep Corrections a Buying Signal?(Chart Of The Day)
Oct 5, 2018The correction has bought many good companies to reasonable valuations. Go against the wisdom of crowd and Buy.
More|
| |
GLENMARK PHARMA SHARE PRICE
Oct 17, 2018 (Close)
TRACK GLENMARK PHARMA
- Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON GLENMARK PHARMA
GLENMARK PHARMA 8-QTR ANALYSIS
COMPARE GLENMARK PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.